Oruka Therapeutics, INC 8-K filings

Oruka Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical pipeline for chronic skin diseases and a robust cash position.

Oruka Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 2, 2026, including the election of directors and ratification of its independent auditor.

Oruka Therapeutics announced positive Week 16 results from its Phase 2a EVERLAST-A trial for ORKA-001 in moderate-to-severe psoriasis, showing significant skin clearance and a favorable safety profile.

Oruka Therapeutics, Inc. announced the appointment of Christopher Martin, a seasoned pharmaceutical commercial leader, to its Board of Directors, following the resignation of Cameron Turtle.

Oruka Therapeutics announced a $180 million private placement and positive interim Phase 1 results for its lead asset, ORKA-001, targeting chronic skin diseases.

Oruka Therapeutics, Inc. has appointed Laura Sandler, formerly Senior Vice President of Operations, as its new Chief Operating Officer, effective July 1, 2025, with a compensation package including a $460,000 base salary and significant equity grants.

Oruka Therapeutics, Inc. announced the successful passage of all proposals at its Annual Meeting of Stockholders on June 2, 2025, including the re-election of two Class I directors and the ratification of its independent auditor.

Oruka Therapeutics secures exclusive worldwide license for IL-17A/F antibodies from Paragon Therapeutics, targeting all fields of use.

Oruka Therapeutics has entered into a licensing agreement with Paragon Therapeutics for exclusive worldwide rights to develop and commercialize IL-23 antibodies, excluding inflammatory bowel disease.

Oruka Therapeutics' stockholders voted to approve the conversion of Series A preferred stock to common stock and authorized the adjournment of a special meeting if needed.

Oruka Therapeutics has filed its audited financial statement as of February 6, 2024, retroactively adjusted for a reverse stock split and merger, revealing a company in its early stages with substantial going concern doubts.

Oruka Therapeutics has amended employment agreements for its CEO and Senior VP of Finance, detailing revised severance benefits and payments.

Oruka Therapeutics has successfully raised approximately $200.5 million through a private placement to fund its research and development efforts.

Oruka Therapeutics has finalized its merger with ARCA biopharma, raising $275 million in a private placement and appointing a new board chairman, with shares now trading on Nasdaq under the symbol ORKA.

ARCA biopharma has updated the special cash dividend amount to $1.613 per share in connection with its merger with Oruka Therapeutics, payable on August 28, 2024.

ARCA biopharma has announced a 1-for-12 reverse stock split, effective September 3, 2024, in preparation for its merger with Oruka Therapeutics, which will result in the combined company trading under the new name Oruka Therapeutics, Inc. and the ticker symbol ORKA.

ARCA biopharma has declared a special cash dividend of approximately $1.59 per share, contingent on shareholder approval of the merger with Oruka Therapeutics.

ARCA Biopharma has agreed to sell its legacy Gencaro and rNAPc2 assets to Genvara Biopharma for $300,000, contingent on the completion of its merger with Oruka Therapeutics.

ARCA biopharma announced its second quarter 2024 financial results, highlighting a net loss of $2.7 million and providing an update on its proposed merger with Oruka Therapeutics.

ARCA biopharma and Oruka Therapeutics have amended their subscription agreement, securing a $275 million investment and issuing warrants to employees and service providers.

ARCA biopharma reported its first quarter 2024 financial results, announced a merger agreement with Oruka Therapeutics, and appointed a new President.

ARCA biopharma has approved a second amendment to retention bonus letters for two executives, increasing their total bonus by 33.33% to $200,000 each.

ARCA biopharma's CEO, Michael Bristow, has departed, with Thomas Keuer, the current COO, stepping in as President and principal executive officer.

ARCA biopharma and Oruka Therapeutics have agreed to merge, creating a company focused on advancing Orukas pipeline of novel biologics for chronic skin diseases, supported by a $275 million private financing.

ARCA biopharma has extended its office lease for six months, with a rent increase starting April 1, 2024.

ARCA biopharma reports the immediate resignation of two board members, Raymond L. Woosley and Dan Mitchell, leading to a reduction in the board size from eight to six directors.

ARCA biopharma announced its 2023 financial results, highlighting a decrease in operating expenses and net loss, while continuing its strategic review process.

ARCA biopharma granted stock options to non-employee directors and held its 2023 Annual Meeting of Stockholders, where directors were elected and other proposals were approved.